tbuckley/cabot-search huggingface dataset:
Improving treatment for Parkinson's disease: Harnessing photothermal and phagocytosis-driven delivery of levodopa nanocarriers across the blood-brain barrier
Authors: Kaili Liang, Li Yang, Jiawei Kang, Bo Liu, Ding Zhang, Liyan Wang, Wei Wang, Qing Wang
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Parkinson's disease (PD) poses a significant therapeutic challenge, mainly due to the limited ability of drugs to cross the blood-brain barrier (BBB) without undergoing metabolic transformations. Levodopa, a key component of dopamine replacement therapy, effectively enhances dopaminergic activity. However, it encounters obstacles from peripheral decarboxylase, hindering its passage through the BBB. Furthermore, levodopa metabolism generates reactive oxygen species (ROS), exacerbating neuronal damage. Systemic pulsatile dosing further disrupts natural physiological buffering mechanisms. In this investigation, we devised a ROS-responsive levodopa prodrug system capable of releasing the drug and reducing ROS levels in the central nervous system. The prodrug was incorporated within second near-infrared region (NIR-II) gold nanorods (AuNRs) and utilized angiopep-2 (ANG) for targeted delivery across the BBB. The processes of tight junction opening and endocytosis facilitated improved levodopa transport. ROS scavenging helped alleviate neuronal oxidative stress, leading to enhanced behavioral outcomes and reduced oxidative stress levels in a mouse model of PD. Following treatment, the PD mouse model exhibited enhanced flexibility, balance, and spontaneous exploratory activity. This approach successfully alleviated the motor impairments associated with the disease model. Consequently, our strategy, utilizing NIR-II AuNRs and ANG-mediated BBB penetration, coupled with the responsive release of levodopa, offers a promising approach for dopamine supplementation and microenvironmental regulation. This system holds substantial potential as an efficient platform for delivering neuroprotective drugs and advancing PD therapy.
Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes
Authors: Yoko Narasaki, Kamyar Kalantar-Zadeh, Andrea C. Daza, Amy S. You, Alejandra Novoa, Renal Amel Peralta, Man Kit Michael Siu, Danh V. Nguyen, Connie M. Rhee
Journal: Diabetes Care (2024)

In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients.
Immunization with germ line–targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques
Authors: Ashley N. Nelson, Xiaoying Shen, Sravani Vekatayogi, Shiyu Zhang, Gabriel Ozorowski, Maria Dennis, Leigh M. Sewall, Emma Milligan, Dominique Davis, Kaitlyn A. Cross, Yue Chen, Jelle van Schooten, Joshua Eudailey, John Isaac, Saad Memon, Carolyn Weinbaum, Hongmei Gao, Sherry Stanfield-Oakley, Alliyah Byrd, Suni Chutkan, Stella Berendam, Kenneth Cronin, Anila Yasmeen, S. Alam, Celia C. LaBranche, Kenneth Rogers, Lisa Shirreff, Albert Cupo, Ronald Derking, Francois Villinger, Per Johan Klasse, Guido Ferrari, Wilton B. Williams, Michael G. Hudgens, Andrew B. Ward, David C. Montefiori, Koen K. A. Van Rompay, Kevin Wiehe, John P. Moore, Rogier W. Sanders, Kristina De Paris, Sallie R. Permar
Journal: Science Immunology (2024)

Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents a low-risk window for HIV acquisition, making early childhood an ideal time for implementing an immunization regimen. Because the elicitation of broadly neutralizing antibodies (bnAbs) is critical for an effective HIV vaccine, our goal was to assess the ability of a bnAb B cell lineage-designed HIV envelope SOSIP (protein stabilized by a disulfide bond between gp120-gp41-named "SOS"-and an isoleucine-to-proline point mutation-named "IP"-at residue 559) to induce precursor CD4 binding site (CD4bs)-targeting bnAbs in early life. Infant rhesus macaques received either a BG505 SOSIP, based on the infant BG505 transmitted/founder virus, or the CD4bs germ line-targeting BG505 SOSIP GT1.1 (
Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site
Authors: Tom G. Caniels, Max Medina-Ramìrez, Shiyu Zhang, Sven Kratochvil, Yuejiao Xian, Ja-Hyun Koo, Ronald Derking, Jakob Samsel, Jelle van Schooten, Simone Pecetta, Edward Lamperti, Meng Yuan, María Ríos Carrasco, Iván del Moral Sánchez, Joel D. Allen, Joey H. Bouhuijs, Anila Yasmeen, Thomas J. Ketas, Jonne L. Snitselaar, Tom P. L. Bijl, Isabel Cuella Martin, Jonathan L. Torres, Albert Cupo, Lisa Shirreff, Kenneth Rogers, Rosemarie D. Mason, Mario Roederer, Kelli M. Greene, Hongmei Gao, Catarina Mendes Silva, Isabel J. L. Baken, Ming Tian, Frederick W. Alt, Bali Pulendran, Michael S. Seaman, Max Crispin, Marit J. van Gils, David C. Montefiori, Adrian B. McDermott, François J. Villinger, Richard A. Koup, John P. Moore, Per Johan Klasse, Gabriel Ozorowski, Facundo D. Batista, Ian A. Wilson, Andrew B. Ward, Rogier W. Sanders
Journal: Science Immunology (2024)

Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based design, engages a diverse range of VRC01-class bnAb precursors. A single immunization with GT1.1 expands CD4 binding site (CD4bs)–specific VRC01-class B cells in knock-in mice and drives VRC01-class maturation. In nonhuman primates (NHPs), GT1.1 primes CD4bs-specific neutralizing serum responses. Selected monoclonal antibodies (mAbs) isolated from GT1.1-immunized NHPs neutralize fully glycosylated BG505 virus. Two mAbs, 12C11 and 21N13, neutralize subsets of diverse heterologous neutralization-resistant viruses. High-resolution structures revealed that 21N13 targets the same conserved residues in the CD4bs as VRC01-class and CH235-class bnAbs despite its low sequence similarity (~40%), whereas mAb 12C11 binds predominantly through its heavy chain complementarity-determining region 3. These preclinical data underpin the ongoing evaluation of GT1.1 in a phase 1 clinical trial in healthy volunteers.
Excessive daytime sleepiness in obstructive sleep apnea: Indirect treatment comparison of wake-promoting agents in patients adherent/nonadherent to primary OSA therapy
Authors: Yuxin Wang, Weijia Zhang, Hui Ye, Yi Xiao
Journal: Sleep Medicine Reviews (2024)

There remains an unmet need for a targeted treatment to address residual excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) after primary treatment. This network meta-analysis evaluated the efficacy and safety of wake-promoting agents (WPAs), namely solriamfetol, pitolisant, modafinil, and armodafinil, for treating residual EDS in patients with OSA. We conducted a comprehensive search which ultimately included 18 studies in the final analysis. All 4 WPAs demonstrated significant therapeutic benefits for the Epworth sleepiness scale (ESS) and maintenance of wakefulness test (MWT). Based on the surface under the cumulative ranking curve (SUCRA) score, solriamfetol, pitolisant, modafinil and armodafinil were ranked from highest to lowest for the ESS. A similar ranking was observed for MWT, where pitolisant was not included in the analysis. The subgroup analysis also evaluated the efficacy of WPAs in the primary treatment adherent and nonadherent subgroups. Regarding adverse reactions, solriamfetol demonstrated the lowest risk of all-cause discontinuation, whereas pitolisant exhibited minimal risks of adverse events leading to treatment discontinuation and treatment-emergent adverse events. Our analysis comprehensively compared the effects and adverse reactions of different WPAs in treating residual EDS in treated patients with OSA. This has significant implications for the practical clinical use of WPAs and future research.
Systematic mapping review of player safety, sport science and clinical care in lacrosse
Authors: Kyle Wallace, Samantha E. Scarneo-Miller, Jennifer Monnin, Andrew E Lincoln, Omar Hraky, Griffith Gosnell, Suin Jeong, Wilson Skinner, Eliana Schaefer, Dharmi K Desai, Shane V Caswell
Journal: British Journal of Sports Medicine (2024)

The objective is to comprehensively classify the types, topics and populations represented in the published lacrosse literature.
Conversion of albumin into a BODIPY-like photosensitizer by a flick reaction, tumor accumulation and photodynamic therapy
Authors: Mengyao Yang, Yujin Kim, So-Yeon Youn, Haengdueng Jeong, Mukesh Eknath Shirbhate, Chanyang Uhm, Gyoungmi Kim, Ki Taek Nam, Sun-Shin Cha, Kwan Mook Kim, Juyoung Yoon
Journal: Biomaterials (2024)
Parkin activates innate immunity and promotes anti-tumor immune responses
Authors: Michela Perego, Minjeong Yeon, Ekta Agarwal, Andrew T. Milcarek, Irene Bertolini, Chiara Camisaschi, Jagadish C. Ghosh, Hsin-Yao Tang, Nathalie Grandvaux, Marcus Ruscetti, Andrew V. Kossenkov, Sarah Preston-Alp, Italo Tempera, Noam Auslander, Dario C. Altieri
Journal: Journal of Clinical Investigation (2024)

The activation of innate immunity and associated interferon (IFN) signaling have been implicated in cancer, but the regulators are elusive and a link to tumor suppression undetermined. Here, we found that Parkin, an E3 ubiquitin ligase altered in Parkinson's Disease was epigenetically silenced in cancer and its re-expression by clinically approved demethylating therapy stimulated transcription of a potent IFN response in tumor cells. This pathway required Parkin E3 ubiquitin ligase activity, involved the subcellular trafficking and release of the alarmin High Mobility Group Box 1 (HMGB1) and was associated with inhibition of NFκB gene expression. In turn, Parkin-expressing cells released an IFN secretome that upregulated effector and cytotoxic CD8 T cell markers, lowered the expression of immune inhibitory receptors, TIM3 and LAG3, and stimulated high content of the self-renewal/stem cell factor, TCF1. Parkin-induced CD8 T cells selectively accumulated in the microenvironment and inhibited transgenic and syngeneic tumor growth, in vivo. Therefore, Parkin is an epigenetically regulated activator of innate immunity and dual mode tumor suppressor, inhibiting intrinsic tumor traits of metabolism and cell invasion, while simultaneously reinvigorating CD8 T cell functions in the microenvironment.
Effects of muscle strength training combined with aerobic training versus aerobic training alone on cardiovascular disease risk indicators in patients with coronary artery disease: a systematic review and meta-analysis of randomised clinical trials
Authors: Tasuku Terada, Robert Pap, Abby Thomas, Roger Wei, Takumi Noda, Sarah Visintini, Jennifer L Reed
Journal: British Journal of Sports Medicine (2024)

To compare the effects of aerobic training combined with muscle strength training (hereafter referred to as combined training) to aerobic training alone on cardiovascular disease risk indicators in patients with coronary artery disease (CAD).
Subcutaneous immunotherapy for bee venom allergy induces epitope spreading and immunophenotypic changes in allergen-specific memory B cells
Authors: Craig I McKenzie, Simone Reinwald, Brett Averso, Brett Spurrier, Andrew Satz, Anouk von Borstel, Sabina Masinovic, Nirupama Varese, Pei Mun Aui, Bruce D Wines, P Mark Hogarth, Mark Hew, Jennifer M Rolland, Robyn E O'Hehir, Menno C van Zelm
Journal: Journal of Allergy and Clinical Immunology (2024)

Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic disorders. We have recently discovered that allergen-specific memory B-cells (Bmem) are phenotypically altered after 4 months sublingual AIT for ryegrass pollen allergy. Whether these effects are shared with subcutaneous AIT (SCIT) and affect the epitope-specificity of Bmem remain unknown.
Multifaceted bone response to immunomodulatory magnesium implants: Osteopromotion at the interface and adipogenesis in the bone marrow
Authors: Heithem Ben Amara, Diana C. Martinez, Kamila Iskhakova, Lena Emanuelsson, Birgitta Norlindh, Anna Johansson Loo, D.C. Florian Wieland, Berit Zeller-Plumhoff, Regine Willumeit-Römer, Tomasz Plocinski, Wojciech Swieszkowski, Furqan A. Shah, Anders Palmquist, Omar Omar, Peter Thomsen
Journal: Biomaterials (2024)

Orthopedic implants made of biodegradable magnesium (Mg) provide an alternative to nondegradable implants for fracture repair. Widely reported to be pro-osteogenic, Mg implants are also believed to be anti-inflammatory and anti-osteoclastic, but this is difficult to reconcile with the early clinical inflammation observed around these implants. Here, by surveying implant healing in a rat bone model, we determined the cellular responses and structural assembly of bone correlated with the surface changes of Mg implants inherent in degradation. We show that, compared to titanium, both high-purity (99.998%) and clinical-grade, rare earth-alloyed (MgYREZr) Mg implants create an initial, transient proinflammatory environment that facilitates inducible nitric oxide synthase-mediated macrophage polarization, osteoclastogenesis, and neoangiogenesis programs. While this immunomodulation subsequently reinforces reparative osteogenesis at the surface of both Mg implants, the faster degradation of high-purity Mg implants, but not MgYREZr implants, elicits a compositional alteration in the interfacial bone and a previously unknown proadipogenic response with persistent low-grade inflammation in the surrounding bone marrow. Beyond the need for rigorous tailoring of Mg implants, these data highlight the need to closely monitor osseointegration not only at the immediate implant surface but also in the peri-implant bone and adjacent bone marrow.
Comparative effectiveness of bivalent BA.4.5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study
Authors: Mie Agermose Gram, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Eero Poukka, Tuija Leino, Rickard Ljung, Niklas Worm Andersson, Anders Hviid
Journal: Journal of Infection (2024)

To estimate the effectiveness and waning of the bivalent BA.4-5 or BA.1 mRNA booster vaccine against Covid-19-related hospitalization and death in immunocompromised individuals.
Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis
Authors: Asma Binte Aziz, Jonathan Dewing Sugimoto, Sye Lim Hong, Young Ae You, Lulu Bravo, Camilo Roa, Charissa Borja-Tabora, May Emmeline B Montellano, Josefina Carlos, Mari Rose A de Los Reyes, Edison R Alberto, Milagros Salvani-Bautista, Hwa Young Kim, Irene Njau, Ralf Clemens, Florian Marks, Birkneh Tilahun Tadesse
Journal: Journal of Infection (2024)
Haematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: an EBMT Inborn Errors Working Party study
Authors: Christo Tsilifis, Carsten Speckmann, Su Han Lum, Thomas A Fox, Adriana Margarit Soler, Yasmina Mozo, Dolores Corral, Anna-Maria Ewins, Rosie Hague, Christina Oikonomopoulou, Krzysztof Kałwak, Katarzyna Drabko, Robert Wynn, Emma C Morris, Suzanne Elcombe, Venetia Bigley, Vassilios Lougaris, Michele Malagola, Fabian Hauck, Petr Sedlacek, Alexandra Laberko, Jennifer M L Tjon, Emilie P Buddingh, Claudia Wehr, Bodo Grimbacher, Andrew R Gennery, Arjan C Lankester, Michael H Albert, Bénédicte Neven, Mary A Slatter
Journal: Journal of Allergy and Clinical Immunology (2024)

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) insufficiency causes a primary immune regulatory disorder characterized by lymphoproliferation, dysgammaglobulinemia, and multiorgan autoimmunity including cytopenias and colitis.
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
Authors: Brenda C O'Connell, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, Jeffrey L Kutok, Judith Varner, Robert Ilaria, Melody A Cobleigh, Dejan Juric, Kate H R Tkaczuk, Anthony Elias, Arielle Lee, Shaker Dakhil, Erika Hamilton, Hatem Soliman, Stephane Peluso
Journal: Journal for ImmunoTherapy of Cancer (2024)

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a poor prognosis particularly in the metastatic setting. Treatments with anti-programmed cell death protein-1/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors (ICI) in combination with chemotherapies have demonstrated promising clinical benefit in metastatic TNBC (mTNBC) but there is still an unmet need, particularly for patients with PD-L1 negative tumors. Mechanisms of resistance to ICIs in mTNBC include the presence of immunosuppressive tumor-associated macrophages (TAMs) in the tumor microenvironment (TME). Eganelisib is a potent and selective, small molecule PI3K-γ inhibitor that was shown in preclinical studies to reshape the TME by reducing myeloid cell recruitment to tumors and reprogramming TAMs from an immune-suppressive to an immune-activating phenotype and enhancing activity of ICIs. These studies provided rationale for the clinical evaluation of eganelisib in combination with the anti-PD-L1 atezolizumab and nab-paclitaxel in firstline mTNBC in the phase 2 clinical trial MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3, NCT03961698). We present here for the first time, in-depth translational analyses from the MARIO-3 study and supplemental data from eganelisib monotherapy Ph1/b study in solid tumors (MARIO-1, NCT02637531).
Unidirectional association of clonal hematopoiesis with atherosclerosis development
Authors: Miriam Díez-Díez, Beatriz L. Ramos-Neble, Jorge de la Barrera, J. C. Silla-Castro, Ana Quintas, Enrique Vázquez, M. Ascensión Rey-Martín, Benedetta Izzi, Lucía Sánchez-García, Inés García-Lunar, Guiomar Mendieta, Virginia Mass, Nuria Gómez-López, Cristina Espadas, Gema González, Antonio J. Quesada, Ana García-Álvarez, Antonio Fernández-Ortiz, Enrique Lara-Pezzi, Ana Dopazo, Fátima Sánchez-Cabo, Borja Ibáñez, Vicente Andrés, Valentín Fuster, José J. Fuster
Journal: Nature Medicine (2024)

Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological cancer and a growing list of nonhematological disorders, most notably atherosclerosis and associated cardiovascular disease. However, whether accelerated atherosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate. Some studies support a direct contribution of certain clonal hematopoiesis-related mutations to atherosclerosis via exacerbation of inflammatory responses, whereas others suggest that clonal hematopoiesis is a symptom rather than a cause of atherosclerosis, as atherosclerosis or related traits may accelerate the expansion of mutant hematopoietic clones. Here we combine high-sensitivity DNA sequencing in blood and noninvasive vascular imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudinal cohort of healthy middle-aged individuals. We found that the presence of a clonal hematopoiesis-related mutation confers an increased risk of developing de novo femoral atherosclerosis over a 6-year period, whereas neither the presence nor the extent of atherosclerosis affects mutant cell expansion during this timeframe. These findings indicate that clonal hematopoiesis unidirectionally promotes atherosclerosis, which should help translate the growing understanding of this condition into strategies for the prevention of atherosclerotic cardiovascular disease in individuals exhibiting clonal hematopoiesis.
Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in COPD: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)
Authors: Dave Singh, Fernando J. Martinez, John R Hurst, MeiLan K. Han, Chris P. Gale, Martin Fredriksson, Dobrawa Kisielewicz, Alec Mushunje, Charlotta Movitz, Nikki Ojili, Himanshu Parikh, Niki Arya, Karin Bowen, Mehul Patel
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

Chronic obstructive pulmonary disease (COPD) is associated with increased risk of cardiovascular and cardiopulmonary events. In the Phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality versus dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Further, the effect of BGF on time to first severe exacerbation has not been reported.
Early vs Delayed Antihypertensive Treatment in Acute Single Subcortical Infarction
Authors: Yufei Wei, Xuewei Xie, Yuesong Pan, Mengxing Wang, Aili Wang, Dacheng Liu, Zilin Zhao, Ximing Nie, Wanying Duan, Xin Liu, Zhe Zhang, Jingyi Liu, Lina Zheng, Suwen Shen, Chongke Zhong, Tan Xu, Yong Jiang, Jing Jing, Xia Meng, Katherine Obst, Chung-Shiuan Chen, Hao Li, Xinyi Leng, David Wang, Yilong Wang, Yonghong Zhang, Jiang He, Yongjun Wang, Liping Liu
Journal: JAMA Network Open (2024)

The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) suggests that early antihypertensive treatment did not reduce the risk of dependency or death in acute ischemic stroke (AIS), compared with delayed treatment. Single subcortical infarction (SSI) is an important stroke subtype, and the association of antihypertensive timing with clinical outcomes is unclear.
Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults
Authors: Kekoa Taparra, Kaeo Kekumano, Ryan Benavente, Luke Roberto, Megan Gimmen, Ryan Shontell, Henrietta Cakobau, Neha Deo, Connor J. Kinslow, Allison Betof Warner, Curtiland Deville, Jaimie Z. Shing, Jacqueline B. Vo, Manali I. Patel, Erqi Pollom
Journal: JAMA Network Open (2024)

There are limited studies assessing stage at diagnosis and risk of death among all 5 federally defined races in the US among adolescent and young adult (AYA) patients with cancer.
NKG2C/<i>KLRC2</i>tumor cell expression enhances immunotherapeutic efficacy against glioblastoma
Authors: Olaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria, Berta Segura-Collar, Juliana Manosalva, Diego Megías, Carlos E De Andrea, Leticia Fernández-Rubio, Aurelio Hernández-Laín, Juan M Sepúlveda-Sánchez, Maria E Rodriguez-Ruiz, Ángel Pérez-Núñez, Derek A Wainwright, Ricardo Gargini, Pilar Sánchez-Gómez
Journal: Journal for ImmunoTherapy of Cancer (2024)

Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize the expression of these receptors in GBM to gain insight into their potential role as modulators of the intratumoral microenvironment.
Cognitive Trajectories in Older Adults Diagnosed With Hematologic Malignant Neoplasms
Authors: Li-Wen Huang, Ying Shi, W. John Boscardin, Michael A. Steinman
Journal: JAMA Network Open (2024)

More people are surviving long-term after diagnosis with hematologic malignant neoplasm (HMN), yet there are limited data on cancer-related cognitive impairment in people with HMN. Better understanding cognitive outcomes after HMN in older adults is important for patient counseling and management.
Racial and Ethnic Disparities in Take-Home Methadone Use for Medicare Beneficiaries With Opioid Use Disorder
Authors: Sugy Choi, Yutong Zhang, Mark Aaron Unruh, Emma E. McGinty, Hye-Young Jung
Journal: JAMA Network Open (2024)

This cross-sectional study examines racial and ethnic disparities in take-home methadone use among Medicare beneficiaries with opioid use disorder following the Substance Abuse and Mental Health Services Administration’s policy change in March 2020.